DrugPatentWatch Database Preview
Par Pharm Inc Company Profile
What is the competitive landscape for PAR PHARM INC, and when can generic versions of PAR PHARM INC drugs launch?
PAR PHARM INC has thirty approved drugs.
There is one US patent protecting PAR PHARM INC drugs. There are seven tentative approvals on PAR PHARM INC drugs.
There are nine patent family members on PAR PHARM INC drugs in eight countries and thirty-seven supplementary protection certificates in ten countries.
Summary for Par Pharm Inc
| International Patents: | 9 |
| US Patents: | 1 |
| Tradenames: | 29 |
| Ingredients: | 29 |
| NDAs: | 30 |
Drugs and US Patents for Par Pharm Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Par Pharm Inc | TRAMADOL HYDROCHLORIDE | tramadol hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 078783-002 | Nov 13, 2009 | AB1 | RX | No | No | ➤ Sign Up | ➤ Sign Up | ||||
| Par Pharm Inc | VIGABATRIN | vigabatrin | FOR SOLUTION;ORAL | 208218-001 | Apr 27, 2017 | AA | RX | No | No | ➤ Sign Up | ➤ Sign Up | ||||
| Par Pharm Inc | OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE | amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil | TABLET;ORAL | 206137-004 | Oct 26, 2016 | AB | RX | No | No | ➤ Sign Up | ➤ Sign Up | ||||
| Par Pharm Inc | DOFETILIDE | dofetilide | CAPSULE;ORAL | 208519-002 | Oct 9, 2018 | AB | RX | No | No | ➤ Sign Up | ➤ Sign Up | ||||
| Par Pharm Inc | TIZANIDINE HYDROCHLORIDE | tizanidine hydrochloride | CAPSULE;ORAL | 207199-001 | Mar 14, 2017 | AB | RX | No | No | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Par Pharm Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Par Pharm Inc | ACCOLATE | zafirlukast | TABLET;ORAL | 020547-003 | Sep 17, 1999 | 5,482,963 | ➤ Sign Up |
| Par Pharm Inc | ACCOLATE | zafirlukast | TABLET;ORAL | 020547-001 | Sep 26, 1996 | 5,583,152 | ➤ Sign Up |
| Par Pharm Inc | ACCOLATE | zafirlukast | TABLET;ORAL | 020547-001 | Sep 26, 1996 | 5,482,963 | ➤ Sign Up |
| Par Pharm Inc | ACCOLATE | zafirlukast | TABLET;ORAL | 020547-001 | Sep 26, 1996 | 5,319,097 | ➤ Sign Up |
| Par Pharm Inc | ACCOLATE | zafirlukast | TABLET;ORAL | 020547-003 | Sep 17, 1999 | 4,859,692 | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for PAR PHARM INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 10 mg and 20 mg | ➤ Subscribe | 2008-02-29 |
International Patents for Par Pharm Inc Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2006115626 | ➤ Sign Up |
| Mexico | 2007013118 | ➤ Sign Up |
| Australia | 2006240490 | ➤ Sign Up |
| Japan | 5378788 | ➤ Sign Up |
| European Patent Office | 1948613 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Par Pharm Inc Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 14/008 | Ireland | ➤ Sign Up | PRODUCT NAME: DEXLANSOPRAZOLE OR A SALT THEREOF; NAT REGISTRATION NO/DATE: PA1864/001/001-002;PA1864/002/001-002 20131125; FIRST REGISTRATION NO/DATE: 47911 47912 47913 47914 20130919 |
| C/GB04/012 | United Kingdom | ➤ Sign Up | PRODUCT NAME: TRAMADOL HYDROCHLORIDE, PARACETAMOL; REGISTERED: FR NL 25970 20020405; UK PL 00242/0384 20030925 |
| C0048 | France | ➤ Sign Up | PRODUCT NAME: AMLODIPINE OU UN DE SES SELS D?ADDITION D?ACIDES PHARMACAUTIQUEMENT ACCEPTABLES/ ATORVASTATINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: NL 29929 DU 20050707; REGISTRATION NO/DATE AT EEC: NL 29929 DU 20050707 |
| 00714 | Netherlands | ➤ Sign Up | PRODUCT NAME: ZOLPIDEM EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; NAT. REGISTRATION NO/DATE: RVG 108438 - 439 20130624; FIRST REGISTRATION: BE424286BE424295 2012180718 |
| 07C/043 | Belgium | ➤ Sign Up | PRODUCT NAME: AMLODIPINE ET VALSARTAN; NATL. REGISTRATION NO/DATE: EU/1/06/370/001 20070118; FIRST REGISTRATION: CH 57771 20061222 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
